Profile data is unavailable for this security.
About the company
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company advancing a pipeline of product candidates enhanced with its proprietary anti-exhaustion technologies for patients with solid tumors or hematologic malignancies. The Company's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to resist exhaustion and kill cancer cells. Its technologies are designed to generate T cells with the ability to persist and self-renew while driving tumor cytotoxicity. Its two product candidates, LYL797 and LYL845, are in Phase I clinical development, and an additional product candidate, LYL119, is entering Phase I clinical development. The Company is also engaged in accelerating the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma.
- Revenue in USD (TTM)54.00k
- Net income in USD-210.26m
- Incorporated2018
- Employees224.00
- LocationLyell Immunopharma Inc201 Haskins Way, Suite 301SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 695-0677
- Fax+1 (302) 531-3150
- Websitehttps://lyell.com/
More ▼
Mergers & acquisitions
| Acquired company | LYEL:NSQ since announced | Transaction value |
|---|---|---|
| ImmPACT Bio USA Inc | 6.09% | 87.50m |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 318.40m | 82.00 | -- | -- | -- | -- | -- | -- | -- | 1.09 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0087 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| Rezolute Inc | 0.00 | -68.46m | 323.32m | 59.00 | -- | 2.46 | -- | -- | -1.33 | -1.33 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -53.39 | -50.36 | -56.66 | -53.25 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.19 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.87m | 328.01m | 10.00 | -- | 3.34 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -50.53m | 330.10m | 57.00 | -- | 1.26 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Codexis Inc | 64.45m | -62.09m | 332.02m | 174.00 | -- | 4.52 | -- | 5.15 | -0.878 | -0.878 | 0.9149 | 0.902 | 0.4259 | 7.03 | 3.62 | 370,379.30 | -41.03 | -17.13 | -54.21 | -20.23 | 75.96 | 77.29 | -96.35 | -37.04 | 3.15 | -- | 0.2806 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| iTeos Therapeutics Inc | 35.00m | -108.14m | 338.56m | 157.00 | -- | 0.51 | -- | 9.67 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| enGene Holdings Inc | 0.00 | -123.44m | 349.30m | 33.00 | -- | 1.52 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
| Lyell Immunopharma Inc | 54.00k | -210.26m | 358.79m | 224.00 | -- | 0.5512 | -- | 6,644.33 | -0.8297 | -0.8297 | 0.0002 | 2.21 | 0.00007 | -- | -- | 241.07 | -28.23 | -- | -29.53 | -- | -- | -- | -389,368.50 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Sutro Biopharma Inc | 169.36m | -124.45m | 359.00m | 304.00 | -- | 2.36 | -- | 2.12 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| XOMA Royalty Corp | 15.24m | -25.10m | 362.49m | 13.00 | -- | 3.61 | -- | 23.79 | -2.22 | -2.22 | 1.17 | 8.58 | 0.0826 | -- | 21.36 | 1,172,231.00 | -9.88 | -4.55 | -10.62 | -4.94 | -- | -- | -119.61 | -31.87 | -- | -- | 0.5471 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Jasper Therapeutics Inc | 0.00 | -62.44m | 370.53m | 45.00 | -- | 3.69 | -- | -- | -5.10 | -5.10 | 0.00 | 6.64 | 0.00 | -- | -- | 0.00 | -52.45 | -- | -57.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -144.32m | 372.89m | 186.00 | -- | 1.93 | -- | -- | -2.19 | -2.19 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -52.83 | -40.85 | -57.18 | -44.48 | -- | -- | -- | -- | -- | -- | 0.1337 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Northwest Biotherapeutics Inc | 1.65m | -75.55m | 380.59m | 25.00 | -- | -- | -- | 231.36 | -0.0644 | -0.0644 | 0.0014 | -0.047 | 0.0581 | -- | -- | 65,800.00 | -260.06 | -381.58 | -- | -- | -- | -- | -4,479.03 | -6,479.25 | -- | -14.10 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| SAGE Therapeutics Inc | 106.40m | -337.59m | 386.00m | 487.00 | -- | 0.6995 | -- | 3.63 | -5.58 | -5.58 | 1.76 | 9.02 | 0.1354 | -- | 5.24 | 218,478.40 | -42.95 | -21.88 | -48.97 | -23.30 | 91.75 | 99.63 | -317.29 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Voyager Therapeutics Inc | 143.77m | 9.02m | 388.82m | 162.00 | 46.47 | 1.16 | 27.99 | 2.70 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Data as of Nov 08 2024. Currency figures normalised to Lyell Immunopharma Inc's reporting currency: US Dollar USD
17.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 11.61m | 4.54% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 10.07m | 3.93% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 7.69m | 3.00% |
| Geode Capital Management LLCas of 30 Jun 2024 | 4.01m | 1.57% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 3.82m | 1.49% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 2.73m | 1.07% |
| MIC Capital Management UK LLPas of 30 Jun 2024 | 1.74m | 0.68% |
| Opaleye Management, Inc.as of 30 Jun 2024 | 1.67m | 0.65% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 1.38m | 0.54% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 1.30m | 0.51% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
